ZeVra Therapeutics saw its shares rise 29% over two days after its drug Miplyffa for Niemann-Pick Disease Type C was granted patent exclusivity through 2041 via the FDA Orange Book listing. The company reported $87.4 million in net sales for FY25, achieved profitability, retired all debt, and holds $236.8 million in cash and investments. Its pipeline focuses on celiprolol for VEDS with orphan and breakthrough therapy designations, facing no clinical competition. Trading at about 9 times estimated FY27 earnings per share, ZeVra offers growth potential, a strong balance sheet, and possible acquisition appeal, making it a candidate for a small investment position.
Crédit Agricole Normandie-Seine reported strong first-half 2026 results with record credit and deposit volumes, a 15.2 million euro increase in net banking income, and a 13.9% rise in net profit to 65.1 million euros. The bank's credit portfolio reac...
Virtual Investor Conferences announced that presentations from the July 22-23 Precious Metals & Critical Minerals Virtual Investor Conference are now available for on-demand viewing for 90 days. Investors can access company materials and schedule one...
BiomX's subsidiary Zorronet has partnered with Czech company Samura s.r.o. to expand its AI-powered monitoring technology across Central and Eastern Europe. The collaborations focus on smart pest management in agriculture and protecting critical tran...
EquipmentShare.com Inc. and some executives face a securities fraud lawsuit alleging they misled investors by not disclosing ongoing related-party transactions after their January 2026 IPO. The complaint claims founder-related entities continued undi...
Heritage Insurance Holdings, a super-regional property and casualty insurer, will announce its second quarter 2026 financial results after market close on August 5, 2026. The company will hold a conference call for investors on August 6 at 9:00am ET ...
